机译:CD CD30在外侧NK NK / T T-CL淋巴瘤中的频繁表达:抗CD CD 30抗体治疗的潜在治疗靶标
Department of Hematology Endocrinology and Metabolism Faculty of MedicineNiigata;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of Hematology Endocrinology and Metabolism Faculty of MedicineNiigata;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of Hematology Endocrinology and Metabolism Faculty of MedicineNiigata;
Department of Hematology Endocrinology and Metabolism Faculty of MedicineNiigata;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of PathologyKurume University School of MedicineKurume Japan;
Department of Hematology Endocrinology and Metabolism Faculty of MedicineNiigata;
antibody therapy; brentuximab vedotin; CD 30; ENKTL; extranodal NK / T ‐cell lymphoma;
机译:CD CD30在外侧NK NK / T T-CL淋巴瘤中的频繁表达:抗CD CD 30抗体治疗的潜在治疗靶标
机译:鼻外结节性NK / T细胞淋巴瘤患者的肿瘤细胞核直径和CD30表达作为潜在的预后参数
机译:鼻外结节性NK / T细胞淋巴瘤患者的肿瘤细胞核直径和CD30表达作为潜在的预后参数
机译:使用基于报道的生物测定和工程化TNFα+和VEGF +靶细胞测量抗TNFα和抗VEGF治疗抗体的FC介导的ADCC和CDC活性的测量
机译:CD16xCD33双特异性杀伤细胞接合剂(BiKE)激活来自骨髓增生异常综合征(MDS)患者的自然杀伤(NK)细胞,以抵抗原发性MDS和髓样抑制细胞(MDSC)CD33阳性靶标。
机译:鼻外结节性NK / T细胞淋巴瘤患者的肿瘤细胞核直径和CD30表达作为潜在的预后参数
机译:用重组抗CD30受体靶向自体CD30 +皮肤淋巴瘤细胞植入T细胞